Relapsing-Remitting Multiple Sclerosis clinical trials at UCLA
2 in progress, 1 open to eligible people
Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
open to eligible people ages 18-50
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Torrance, California and other locations
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sorry, in progress, not accepting new patients
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.
Los Angeles, California and other locations
Our lead scientists for Relapsing-Remitting Multiple Sclerosis research studies include Bijal Mehta.
Last updated: